迈威生物创新药9MW1911公布IIa期临床研究结果

Core Viewpoint - Maiwei Biotech (688062) announced the completion of Phase IIa clinical study for its innovative drug 9MW1911 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) [1] Group 1: Clinical Study Results - The study involved 80 patients with moderate to severe COPD, with a control group of 20 patients receiving a placebo [1] - All dosage groups of 9MW1911 demonstrated good safety and tolerability compared to the placebo [1] - The annualized exacerbation rate of moderate COPD decreased by over 30% at the recommended Phase IIb dose (N=30) compared to the placebo group [1] - The annualized exacerbation rate for severe COPD decreased by over 40% compared to the placebo group [1] - The proportion of patients experiencing severe exacerbations was significantly lower in the treatment group (13.3% vs 35%) compared to the placebo group [1]